Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

000963 Huadong Medicine Co.,Ltd.

Closed 03-26 15:00:00

33.50

-0.66

-1.93%

High34.71	Low33.42	Vol7.75M
Open34.08	D1 Closing34.16	Amplitude3.78%
Mkt Cap58.76B	Tradable Cap58.73B	Total Shares1.75B
T/O264.00M	T/O Rate0.44%	Tradable Shares1.75B
P/B2.48	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":33.5,"timestamp":1774508589000,"preClose":34.16,"halted":0,"volume":7752940,"delay":0,"changeRate":-0.0193,"floatShares":1753000000,"shares":1754000000,"eps":2.1085,"marketStatus":"Closed","change":-0.66,"latestTime":"03-26 15:00:00","open":34.08,"high":34.71,"low":33.42,"amount":264000000,"amplitude":0.0378,"askPrice":33.51,"askSize":10,"bidPrice":33.5,"bidSize":250,"shortable":0,"etf":0,"ttmEps":2.1085,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.16,"symbolType":"stock","openAndCloseTimeList":[[1774488600000,1774495800000],[1774501200000,1774508400000]],"highLimit":37.58,"lowLimit":30.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":2.48,"roa":"--","peRate":15.888072,"roe":"11.39%","epsLYR":2.0046,"committee":0.337423,"marketValue":58750000000,"turnoverRate":0.0044,"status":1,"floatMarketCap":58726000000},"requestUrl":"/m/hq/s/000963/wiki","defaultTab":"wiki","newsList":[{"id":"1109379648","title":"Huadong Medicine Subsidiary Gets Nod for HDM2024 Injection Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1109379648","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109379648?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:35","pubTimestamp":1774517701,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received a drug clinical trial approval notice from the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0175","BK0196","000963","BK0209","BK0187","LU2328871848.SGD","BK0132","LU1969619763.USD","BK0188"],"gpt_icon":0},{"id":"2618909714","title":"Huadong Medicine Unit Gets US FDA's Nod to Trial Advanced Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2618909714","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618909714?lang=en_us&edition=fundamental","pubTime":"2026-03-12 11:37","pubTimestamp":1773286635,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from the U.S. Food and Drug Administration for the clinical trial of injectable HDM2024, according to a Thursday disclosure on the Shenzhen bourse.The Chinese drugmaker will conduct phase I clinical trials to test the drug as a treatment for advanced solid tumors in the U.S.The company's shares slipped over 1% during the morning trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0757428866.USD","IE00B66KJ199.SGD","BK0175","IE00B19Z4B17.USD","BK0209","IE00B7SZL793.SGD","BK0196","IE0031619046.USD","BK0183","000963","AEIS","LABU","LU1815336091.USD","BK4157","BK4585","BK4588","LU1969619763.USD","BK0132","LU2328871848.SGD","BK0188","BK0187"],"gpt_icon":0},{"id":"1165877473","title":"Huadong Medicine's Investigational Drug HDM2024 Receives FDA Clearance for US Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1165877473","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165877473?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:46","pubTimestamp":1773229589,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co., Ltd. (000963.SZ) announced that on March 10, 2026, its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received notification from the U.S. Food and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK0187","BK0132","BK0196","BK0175","LABU","BK0188","BK4585","BK4588","LU2328871848.SGD","000963","BK0183","BK0209"],"gpt_icon":0},{"id":"1108655208","title":"Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=1108655208","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108655208?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:28","pubTimestamp":1772807329,"startTime":"0","endTime":"0","summary":"The global weight-loss drug market is entering a new phase, driven by the launch of oral formulations, upcoming generic competition, and price reductions in the United States for blockbuster products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1894683264.USD","LU1969619763.USD","LU0306807586.USD","LU2097828474.EUR","LU0868494617.USD","RHHBY","LU1066053197.SGD","LU2097828714.EUR","LU1023059063.AUD","BK1583","BK4585","LU2097828631.EUR","VKTX","LU0306806265.USD","IE00BLSP4452.SGD","BK4534","LU1894683348.USD","SG9999001176.USD","SG9999002232.USD","HK0000165453.HKD","BK4581","LU0289739699.SGD","LU0058720904.USD","LU2328871848.SGD","BK4588","BK4550","IE0002270589.USD","LU0225284248.USD","NVO","IE00B19Z3581.USD","LU1057294990.SGD","BK4568","LU1066051498.USD","LU0985481810.HKD","LU2242644610.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","AZN","BK4007","PFE","BK4599","SG9999002224.SGD","LU0502904849.HKD","BK4533","LU0455707207.USD","LU0321505868.SGD","LU2488822045.USD","LU1883839398.USD","LU0321505439.SGD","SG9999003800.SGD","LU0122379950.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LLY","LU0170899867.USD","SG9999001176.SGD","BK1589","000963","LU2097828557.USD","MRK","BK4592","LU2097828805.USD","SG9999013999.USD","LU0225771236.USD","LU0456855351.SGD","LU0234572021.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","01801"],"gpt_icon":1},{"id":"2617687841","title":"CARsgen posts FY2025 net loss of CNY103 million, down 87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687841","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687841?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798697,"startTime":"0","endTime":"0","summary":"CARsgen reported FY 2025 revenue of CNY 125.7 million, mainly from zevor-cel, and FY 2025 gross profit of about CNY 80 million. The company posted a FY 2025 net loss of about CNY 103 million, down about 87% YoY. Cash and cash equivalents were about CNY 1.1 billion as of Dec. 31, 2025, and CARsgen said cash and cash equivalents at the end of 2026 are expected to be not less than CNY 1.0 billion. For 2025 commercialization, CARsgen said it received 218 confirmed zevor-cel orders from partner Huadong Medicine, and noted zevor-cel was included in China’s Commercial Health Insurance Innovative Drug Catalogue  in December 2025. On the pipeline, the company said China’s regulator accepted the NDA for satri-cel and granted Priority Review; CARsgen expects satri-cel to be approved in H1 2026 and initiate commercialization. CARsgen also highlighted progress in allogeneic CAR-T development and its lentiviral-based in vivo CAR T-cell CARvivo platform, and disclosed a Feb. 12, 2026 strategic cooper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL11T47r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0187","000963","BK1585","BK0183","BK1587","LU2328871848.SGD","BK1574","BK0188","LU1969619763.USD","02171","BK1161","BK0196","BK0209","BK0132"],"gpt_icon":0},{"id":"2617876356","title":"Press Release: CARsgen Therapeutics Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617876356","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617876356?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798640,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.-- Cash and cash equivalents were around RMB1,123 million as of December 31,2025. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,000 million. The net loss for the year ended December 31,2025 was RMB103 million, representing a decrease of approximately 87%. compared to the year ended December 31, 2024. In light of operational. factors such as the changes in operating cash flow, we expect to have. -- During 2025, CARsgen has received a total of 218 confirmed orders of. zevor-cel from its commercialization partner Huadong Medicine. In. December 2025, zevor-cel has been included in China's Commercial Health. -- The Center for Drug Evaluation  of the National Medical Products.  and granted Priority Review for satri-cel. The results of satri-cel. confirmatory Phase II trial i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TM","000963","BK0175","R","BK1585","LENZ","BK1161","BK4099","BK4195","CDE","BK4230","LU1223082519.USD","OS","BK4585","BK0132","BK4097","BK0209","BK4555","LU2328871848.SGD","BK0183","BK4211","CAR","BK0188","BK4022","BK0187","BK4604","BK1574","BK4232","PFS","BK0196","BK1587","LU1223082196.USD","BK4017","BK4588","BK4539","LU1969619763.USD","02171","LU1223083913.SGD","03160","BK4139"],"gpt_icon":0},{"id":"1161853709","title":"Huadong Medicine Co.,Ltd. Announces Controlling Shareholder Releases 49 Million Shares from Pledge","url":"https://stock-news.laohu8.com/highlight/detail?id=1161853709","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161853709?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:21","pubTimestamp":1772796112,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. disclosed that its controlling shareholder, China Grand Enterprises (Group) Co., Ltd., has recently released a portion of its pledged shares. The number of shares released from pledge amounts to 49 million.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0183","BK0196","BK0187","BK0175","BK0209","BK0132","LU1969619763.USD","LU2328871848.SGD","000963"],"gpt_icon":0},{"id":"2616313527","title":"Huadong Medicine Obtains Greenlight for Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616313527","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616313527?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:10","pubTimestamp":1772518246,"startTime":"0","endTime":"0","summary":"Huadong Medicine  subsidiary Zhejiang Doer Biologics obtained the approval of China's drug regulator to conduct clinical trials for DR30206 combined with chemotherapy to treat non-small cell lung cancer.DR30206 is designed to restore immune response while inhibiting tumor growth, according to a Wednesday filing with the Shenzhen bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0196","BK0209","BK0175","BK0183","LU1969619763.USD","BK0132","000963","BK0188","LU2328871848.SGD"],"gpt_icon":0},{"id":"1173704499","title":"Huadong Medicine's Subsidiary Gains Approval for Clinical Trial of DR30206 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1173704499","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173704499?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:01","pubTimestamp":1772449279,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) has announced that its subsidiary, Zhejiang Doer Biologics Co., Ltd., recently received a clinical trial approval notice from the National Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0209","000963","BK0132","BK0196","BK0175","LU2328871848.SGD","LU1969619763.USD","BK0188","BK0187"],"gpt_icon":0},{"id":"1104849308","title":"Huadong Medicine Appeals to Supreme Court After Losing Initial Patent Lawsuit Against Jolly Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1104849308","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104849308?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:14","pubTimestamp":1772158459,"startTime":"0","endTime":"0","summary":"Following an unsuccessful initial ruling, Huadong Medicine Co.,Ltd. has proceeded with an appeal. On the evening of February 26, Zhejiang Jolly Pharmaceutical Co.,Ltd. announced that due to a patent...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0196","BK0209","300181","LU1969619763.USD","BK0175","BK0042","BK0188","LU2328871848.SGD","BK0077","BK0239","000963","BK0183","BK0132"],"gpt_icon":0},{"id":"2609344880","title":"Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609344880","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609344880?lang=en_us&edition=fundamental","pubTime":"2026-02-05 12:15","pubTimestamp":1770264933,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) unit, Zhejiang Doer Biologics, obtained approval from China's National Medical Products Administration for the clinical trial of DR10624 injection, according to a Shenz","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","000963","BK0188","BK0183","LU1969619763.USD","BK0187","BK0175","LU2328871848.SGD","BK0132","BK0209"],"gpt_icon":0},{"id":"1179334322","title":"Huadong Medicine Subsidiary's DR10624 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1179334322","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179334322?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:56","pubTimestamp":1770198974,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its subsidiary, Zhejiang Daoer Biotechnology Co., Ltd., has obtained a \"Drug Clinical Trial Approval Notice\" issued by the National Medical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK0183","000963","BK0209","BK0187","BK0175","BK0188","LU1969619763.USD","BK0196","BK0132"],"gpt_icon":0},{"id":"2608401336","title":"China's Drug Regulator Accepts Marketing Authorization Application of Huadong Medicine's Unit for Roflumilast Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2608401336","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608401336?lang=en_us&edition=fundamental","pubTime":"2026-02-04 11:56","pubTimestamp":1770177378,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the marketing authorization application from Huadong Medicine's  unit, Hangzhou Sino-American Huadong Pharmaceutical, for roflumilast cream, according to a Wednesday disclosure on the Shenzhen bourse.The overseas-manufactured drug, also named Zoryve, was developed for the topical treatment of mild to moderate atopic dermatitis in patients aged 2 to 5 years.Hangzhou Sino-American received exclusive rights from Arcutis Biotherapeutics to distribute the drug in China and Southeast Asia.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0183","000963","BK0209","BK0187","BK0175","BK0188","LU1969619763.USD","BK0196","BK0132"],"gpt_icon":0},{"id":"1120635069","title":"Huadong Medicine (000963.SZ): Roflumilast Cream Marketing Authorization Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1120635069","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120635069?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:16","pubTimestamp":1770117382,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Zhongmei Huadong), has received a \"Notice of Acceptance\" issued...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0209","000963","BK0132","BK0196","BK0175","LU2328871848.SGD","LU1969619763.USD","BK0188","BK0187"],"gpt_icon":0},{"id":"1117243250","title":"Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market","url":"https://stock-news.laohu8.com/highlight/detail?id=1117243250","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117243250?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:41","pubTimestamp":1769514072,"startTime":"0","endTime":"0","summary":"On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","LU1969619763.USD","000963","BK4144","BK0196","BK0183","BK0132","BK0209","GLP","BK0175","LU2328871848.SGD","BK0188","BK0187"],"gpt_icon":0},{"id":"2603962406","title":"Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603962406","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603962406?lang=en_us&edition=fundamental","pubTime":"2026-01-15 10:55","pubTimestamp":1768445746,"startTime":"0","endTime":"0","summary":"Huadong Medicine (SHE:000963) subsidiary Dual Bio received the approval of the U.S. Food and Drug Administration to begin clinical trials for DR10624 injection.DR10624 is indicated for metabolic dysfunction-associated steatotic liver disease, according to a Thursday filing with the Shenzhen bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000963","BK0132","BK0183","BK0187","BK0196","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0188","BK0175"],"gpt_icon":0},{"id":"2602059573","title":"Huadong Medicine's Hypertriglyceridemia Drug Gains Breakthrough Status in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2602059573","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602059573?lang=en_us&edition=fundamental","pubTime":"2026-01-12 14:26","pubTimestamp":1768199163,"startTime":"0","endTime":"0","summary":"Huadong Medicine (SHE:000963) subsidiary Duality Biotech's novel drug, DR10624 injection, was included in China's breakthrough therapy designation list.DR10624 is indicated for severe hypertriglycerid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK0187","BK0132","BK0196","BK0175","BK0188","LU2328871848.SGD","000963","BK0183","BK0209"],"gpt_icon":0},{"id":"1144466352","title":"Key Market Catalysts for January 12, 2026: Seven Major Positive Developments to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=1144466352","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144466352?lang=en_us&edition=fundamental","pubTime":"2026-01-11 22:11","pubTimestamp":1768140673,"startTime":"0","endTime":"0","summary":"On January 11, several listed companies announced positive developments. Defu Technology (301511.SZ) disclosed that it recently signed a Letter of Intent for Acquisition with Anhui Huiru Technology...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0194","BK0196","BK0214","BK0238","SINA","002746","BK0132","LU1969619763.USD","BK0209","000963","BK0188","BK0175","301511","BK0256","BK0187","002969","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591961930","title":"China Court Dismisses Huadong Medicine Unit's Copyright Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2591961930","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591961930?lang=en_us&edition=fundamental","pubTime":"2025-12-15 16:25","pubTimestamp":1765787158,"startTime":"0","endTime":"0","summary":"A court in Zhejiang, China, dismissed the case filed by Huadong Medicine  subsidiary Hangzhou Sino-American Huadong Pharmaceutical against three defendants for alleged patent infringement, according to a Monday filing with the Shenzhen bourse.Huadong claimed that one of the defendants, Qinghai Zhufeng Cordyceps Raw Material, copied the listed company's raw material for its Bailin capsules and submitted fake documents, the filing said.The company will file an appeal with China's Supreme People's Court, it said.Shares fell 3% during the close of trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0132","BK0183","BK0187","BK0196","LU1969619763.USD","BK0209","LU2328871848.SGD","000963","BK0175","BK0188"],"gpt_icon":0},{"id":"2589863953","title":"Huadong Medicine's Two Drugs Placed in China's Insurance Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589863953","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589863953?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:24","pubTimestamp":1765167864,"startTime":"0","endTime":"0","summary":"Two of Huadong Medicine's  drugs were included in China's National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List, according to a Shenzhen bourse filing on Monday.The drugs are senaparib capsules and lina-raserate dimethyl ester capsules.The new list will be effective on Jan. 1, 2026, the Chinese drugmaker said.Meanwhile, the company's zevokio lensa injection was included in the commercial health insurance innovative drug list, while the ustekinumab injection was moved to routine catalog management, with changes to its reimbursement scope.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0183","000963","BK0209","BK0187","BK0175","BK0188","LU1969619763.USD","BK0196","BK0132"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","stockEarnings":[{"period":"1week","weight":-0.06},{"period":"1month","weight":-0.07},{"period":"3month","weight":-0.1562},{"period":"6month","weight":-0.1972},{"period":"1year","weight":0.0137},{"period":"ytd","weight":-0.1508}],"companyName":"华东医药股份有限公司","boardCode":"AI0052","perCapita":"25482股","boardName":"零售业","registeredCapital":"175373万元","compareEarnings":[{"period":"1week","weight":-0.0293},{"period":"1month","weight":-0.0555},{"period":"3month","weight":-0.0188},{"period":"6month","weight":0.0159},{"period":"1year","weight":0.1545},{"period":"ytd","weight":-0.0201}],"survey":"　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。","serverTime":1774543394100,"listedPrice":5.76,"stockholders":"68793人(较上一季度减少1.50%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}